Your browser doesn't support javascript.
loading
Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer.
Diaz-Lagares, Angel; Crujeiras, Ana B; Lopez-Serra, Paula; Soler, Marta; Setien, Fernando; Goyal, Ashish; Sandoval, Juan; Hashimoto, Yutaka; Martinez-Cardús, Anna; Gomez, Antonio; Heyn, Holger; Moutinho, Catia; Espada, Jesús; Vidal, August; Paúles, Maria; Galán, Maica; Sala, Núria; Akiyama, Yoshimitsu; Martínez-Iniesta, María; Farré, Lourdes; Villanueva, Alberto; Gross, Matthias; Diederichs, Sven; Guil, Sonia; Esteller, Manel.
  • Diaz-Lagares A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Crujeiras AB; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Lopez-Serra P; Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto Salud Carlos III, 28029 Madrid, Spain.
  • Soler M; Endocrine Division, Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.
  • Setien F; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Goyal A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Sandoval J; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Hashimoto Y; Division of RNA Biology and Cancer (B150), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Martinez-Cardús A; Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Gomez A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Heyn H; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Moutinho C; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Espada J; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Vidal A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Paúles M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Galán M; Experimental Dermatology and Skin Biology Group, Ramón y Cajal Institute for Biomedical Research (IRYCIS), Ramón y Cajal University Hospital, 28034 Madrid, Spain.
  • Sala N; Bionanotechnology Laboratory, Bernardo O'Higgins University, Santiago 8370854, Chile.
  • Akiyama Y; Pathology Department, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Catalonia, Spain.
  • Martínez-Iniesta M; Pathology Department, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Catalonia, Spain.
  • Farré L; Department of Medical Oncology, Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Villanueva A; Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, ICO, IDIBELL, 08908 Barcelona, Catalonia, Spain.
  • Gross M; Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 113-8510 Tokyo, Japan.
  • Diederichs S; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L'Hospitalet del Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Guil S; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L'Hospitalet del Llobregat, 08908 Barcelona, Catalonia, Spain.
  • Esteller M; Laboratory of Experimental Pathology (LAPEX), Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPQGM/FIOCRUZ) and National Institute of Science and Technology of Tropical Diseases (INCT/DT), 40296710 Salvador, Bahia, Brazil.
Proc Natl Acad Sci U S A ; 113(47): E7535-E7544, 2016 11 22.
Article en En | MEDLINE | ID: mdl-27821766
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Proteínas de Unión al ADN / Proteína 1 de Unión a la Caja Y / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Proteínas de Unión al ADN / Proteína 1 de Unión a la Caja Y / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2016 Tipo del documento: Article